OA11787A - Method for preventing or delaying catheter-based revascularization. - Google Patents

Method for preventing or delaying catheter-based revascularization. Download PDF

Info

Publication number: OA11787A
Authority: OA; OAPI
Prior art keywords: patients; study; cholestérol; use according; atorvastatin
Prior art date: 1998-09-30

Application number

OA1200100080A

Other languages

English (en)

Inventor

Donald Michael Black

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-30

Filing date

1999-07-08

Publication date

2005-07-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22289955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA11787(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-07-08 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

2005-07-26 Publication of OA11787A publication Critical patent/OA11787A/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Emergency Medicine (AREA)
Organic Chemistry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Diabetes (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Materials For Medical Uses (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Surgical Instruments (AREA)
Media Introduction/Drainage Providing Device (AREA)

OA1200100080A 1998-09-30 1999-07-08 Method for preventing or delaying catheter-based revascularization. OA11787A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US10245798P	1998-09-30	1998-09-30

Publications (1)

Publication Number	Publication Date
OA11787A true OA11787A (en)	2005-07-26

Family

ID=22289955

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200100080A OA11787A (en)	1998-09-30	1999-07-08	Method for preventing or delaying catheter-based revascularization.

Country Status (34)

Country	Link
US (1)	US20080119561A1 (id)
EP (1)	EP1117392B1 (id)
JP (1)	JP2002525321A (id)
KR (1)	KR20010079955A (id)
CN (1)	CN1197565C (id)
AP (1)	AP1708A (id)
AT (1)	ATE260100T1 (id)
AU (1)	AU768474B2 (id)
BG (1)	BG105471A (id)
BR (1)	BR9914098A (id)
CA (1)	CA2343299C (id)
CZ (1)	CZ20011035A3 (id)
DE (1)	DE69915084T2 (id)
DK (1)	DK1117392T3 (id)
EA (1)	EA007427B1 (id)
EE (1)	EE200100199A (id)
ES (1)	ES2214872T3 (id)
HR (1)	HRP20010236A2 (id)
HU (1)	HUP0103648A3 (id)
ID (1)	ID30255A (id)
IL (2)	IL141953A0 (id)
IS (1)	IS5889A (id)
NO (1)	NO20011615L (id)
NZ (1)	NZ510500A (id)
OA (1)	OA11787A (id)
PL (1)	PL346980A1 (id)
PT (1)	PT1117392E (id)
SI (1)	SI1117392T1 (id)
SK (1)	SK4122001A3 (id)
TR (1)	TR200100901T2 (id)
UA (1)	UA73292C2 (id)
WO (1)	WO2000018395A1 (id)
YU (1)	YU23901A (id)
ZA (1)	ZA200102230B (id)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUP0203326A3 (en)	1999-08-30	2003-04-28	Sanofi Aventis Deutschland	Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
WO2001078747A1 (de) *	2000-04-18	2001-10-25	Bayer Aktiengesellschaft	Verwendung von cse-hemmern zur behandlung von herzinsuffizienz
AU2001264731A1 (en) *	2000-07-14	2002-01-30	Warner-Lambert Company	Treatment of eating disorders using carboxyalkylethers
US6982251B2 (en)	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
RS20100015A (sr)	2001-01-26	2010-12-31	Schering Corporation	Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
PT1355644E (pt)	2001-01-26	2006-11-30	Schering Corp	Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
US7071181B2 (en)	2001-01-26	2006-07-04	Schering Corporation	Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7056906B2 (en)	2001-09-21	2006-06-06	Schering Corporation	Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
EP1429756B1 (en)	2001-09-21	2006-11-22	Schering Corporation	Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US7053080B2 (en)	2001-09-21	2006-05-30	Schering Corporation	Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
JP2006508188A (ja)	2002-11-06	2006-03-09	シェーリング　コーポレイション	脱髄の処置のためのコレステロール吸収インヒビター
DE602004016123D1 (de)	2003-03-07	2008-10-09	Schering Corp	Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
CN1756755A (zh)	2003-03-07	2006-04-05	先灵公司	取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
CN1756756A (zh)	2003-03-07	2006-04-05	先灵公司	取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5157025A (en) *	1991-04-01	1992-10-20	E. R. Squibb & Sons, Inc.	Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US5807388A (en) *	1994-05-25	1998-09-15	The Trustees Of Columbia University In The City Of New York	Myocardial revascularization through the endocardial surface using a laser
WO1995013063A1 (en) *	1993-11-09	1995-05-18	Merck & Co., Inc.	HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION
US5545628A (en) *	1995-01-10	1996-08-13	Galephar P.R. Inc.	Pharmaceutical composition containing fenofibrate
US5648387A (en) *	1995-03-24	1997-07-15	Warner-Lambert Company	Carboxyalkylethers, formulations, and treatment of vascular diseases
CN1217656C (zh) *	1995-11-02	2005-09-07	沃尼尔·朗伯公司	用于调节脂浓度的方法和药物组合物
SE506272C2 (sv) *	1996-03-18	1997-11-24	Paul Edholm	Förfarande och anordning för att bestämma bildläge och bildvinkel i en röntgenbild
IL117702A0 (en) *	1996-03-28	1996-07-23	Tel Aviv Medical Center Resear	Drug for hyperlipoproteinemia
AU3667297A (en) *	1996-07-09	1998-02-02	Merck & Co., Inc.	Therapy for combined hyperlipidemia
US5861399A (en) *	1996-07-17	1999-01-19	Heart Care Partners	Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US6180660B1 (en) *	1997-08-26	2001-01-30	Merck & Co., Inc.	Cholesterol-lowering therapy
NZ503982A (en) *	1997-12-12	2002-03-28	Warner Lambert Co	Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus

1999
- 1999-07-08 OA OA1200100080A patent/OA11787A/en unknown
- 1999-07-08 EA EA200100370A patent/EA007427B1/ru not_active IP Right Cessation
- 1999-07-08 ES ES99933763T patent/ES2214872T3/es not_active Expired - Lifetime
- 1999-07-08 AP APAP/P/2001/002112A patent/AP1708A/en active
- 1999-07-08 CN CNB998116297A patent/CN1197565C/zh not_active Expired - Fee Related
- 1999-07-08 NZ NZ510500A patent/NZ510500A/xx unknown
- 1999-07-08 CZ CZ20011035A patent/CZ20011035A3/cs unknown
- 1999-07-08 SK SK412-2001A patent/SK4122001A3/sk unknown
- 1999-07-08 YU YU23901A patent/YU23901A/sh unknown
- 1999-07-08 SI SI9930535T patent/SI1117392T1/xx unknown
- 1999-07-08 DK DK99933763T patent/DK1117392T3/da active
- 1999-07-08 TR TR2001/00901T patent/TR200100901T2/xx unknown
- 1999-07-08 IL IL14195399A patent/IL141953A0/xx active IP Right Grant
- 1999-07-08 HR HR20010236A patent/HRP20010236A2/hr not_active Application Discontinuation
- 1999-07-08 AU AU49750/99A patent/AU768474B2/en not_active Ceased
- 1999-07-08 BR BR9914098-5A patent/BR9914098A/pt not_active Application Discontinuation
- 1999-07-08 AT AT99933763T patent/ATE260100T1/de not_active IP Right Cessation
- 1999-07-08 WO PCT/US1999/015385 patent/WO2000018395A1/en not_active Ceased
- 1999-07-08 CA CA002343299A patent/CA2343299C/en not_active Expired - Fee Related
- 1999-07-08 EE EEP200100199A patent/EE200100199A/xx unknown
- 1999-07-08 JP JP2000571914A patent/JP2002525321A/ja active Pending
- 1999-07-08 DE DE69915084T patent/DE69915084T2/de not_active Revoked
- 1999-07-08 KR KR1020017004021A patent/KR20010079955A/ko not_active Ceased
- 1999-07-08 EP EP99933763A patent/EP1117392B1/en not_active Revoked
- 1999-07-08 PL PL99346980A patent/PL346980A1/xx not_active Application Discontinuation
- 1999-07-08 PT PT99933763T patent/PT1117392E/pt unknown
- 1999-07-08 HU HU0103648A patent/HUP0103648A3/hu unknown
- 1999-07-08 ID IDW20010902A patent/ID30255A/id unknown
- 1999-08-07 UA UA2001042933A patent/UA73292C2/uk unknown
2001
- 2001-03-12 IL IL141953A patent/IL141953A/en not_active IP Right Cessation
- 2001-03-14 IS IS5889A patent/IS5889A/is unknown
- 2001-03-16 ZA ZA200102230A patent/ZA200102230B/en unknown
- 2001-03-29 NO NO20011615A patent/NO20011615L/no not_active Application Discontinuation
- 2001-04-25 BG BG105471A patent/BG105471A/xx unknown
2007
- 2007-11-28 US US11/946,217 patent/US20080119561A1/en not_active Abandoned

Also Published As

Publication number	Publication date
UA73292C2 (en)	2005-07-15
CZ20011035A3 (cs)	2001-10-17
ES2214872T3 (es)	2004-09-16
CA2343299A1 (en)	2000-04-06
AU4975099A (en)	2000-04-17
ID30255A (id)	2001-11-15
BG105471A (bg)	2001-12-31
CN1342072A (zh)	2002-03-27
AP2001002112A0 (en)	2001-06-30
NO20011615L (no)	2001-04-24
EP1117392B1 (en)	2004-02-25
PL346980A1 (en)	2002-03-11
SK4122001A3 (en)	2002-06-04
BR9914098A (pt)	2001-07-31
YU23901A (sh)	2003-07-07
SI1117392T1 (en)	2004-06-30
EP1117392A1 (en)	2001-07-25
CA2343299C (en)	2008-04-01
IS5889A (is)	2001-03-14
AP1708A (en)	2007-01-10
EE200100199A (et)	2002-06-17
AU768474B2 (en)	2003-12-11
DE69915084T2 (de)	2004-07-22
DK1117392T3 (da)	2004-06-14
DE69915084D1 (de)	2004-04-01
HUP0103648A2 (hu)	2003-08-28
PT1117392E (pt)	2004-07-30
IL141953A (en)	2006-07-05
HUP0103648A3 (en)	2003-10-28
ATE260100T1 (de)	2004-03-15
JP2002525321A (ja)	2002-08-13
IL141953A0 (en)	2002-03-10
WO2000018395A1 (en)	2000-04-06
NO20011615D0 (no)	2001-03-29
TR200100901T2 (tr)	2001-08-21
CN1197565C (zh)	2005-04-20
KR20010079955A (ko)	2001-08-22
US20080119561A1 (en)	2008-05-22
EA200100370A1 (ru)	2001-10-22
NZ510500A (en)	2003-10-31
ZA200102230B (en)	2002-06-18
EA007427B1 (ru)	2006-10-27
HRP20010236A2 (en)	2002-04-30
HK1042436A1 (en)	2002-08-16

Publication	Publication Date	Title
US20080119561A1 (en)	2008-05-22	Methods for preventing or delaying catheter- based resvascularization
Ericsson et al.	1997	Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT])
JPH07206712A (ja)	1995-08-08	ＨＭＧＣｏＡレダクターゼインヒビターを用いる心臓血管の疾患の発生の危険を予防または減少する方法
EP1045691B1 (en)	2004-12-29	Statin-carboxyalkylether combinations
Koren et al.	2009	Impact of High‐Dose Atorvastatin in Coronary Heart Disease Patients Age 65 to 78 Years
Kasai et al.	2007	Long-term (11-year) statin therapy following percutaneous coronary intervention improves clinical outcome and is not associated with increased malignancy
EP1296716B1 (en)	2006-11-08	Use of a beta-blocker for the treatment of atherosclerosis
MXPA01003290A (es)	2002-02-26	Metodo para prevenir o retardar la revascularizacion a base de cateteres
US20030105154A1 (en)	2003-06-05	Statin-carboxyalkylether combinations
Hermayer	2004	Treatment of lipids and type 2 diabetes
Roberts	2014	Gender-specific aspects of cardiovascular disease
WO2012116997A1 (en)	2012-09-07	TREATMENT OF ARTERIAL AGEING BY HMG CoA REDUCTASE INHIBITOR
McKenney et al.	2008	Safety profile of extended-release niacin/laropiprant in patients with dyslipidemia
Dastani	2005	Assessment of drug utilization patterns, medication compliance and physician adherence to lipid and safety monitoring guidelines among patients on lipid-lowering drugs in the Texas Medicaid system
Gnasso et al.	1994	Simvastatin in the treatment of patients with hypercholesterolemia and associated coronary heart disease risk factors: An Italian multicenter study
US20050059741A1 (en)	2005-03-17	Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxygenase-1